In this study we thus aimed to characterize the impact of Recifercept, a novel therapy based on the extracellular domain of human FGFR3,(22) on the premature closure of the cranial base synchondroses in a mouse model of achondroplasia carrying the G380R mutation in the FGFR3 gene. The gene discussed is FGFR3; the disease is achondroplasia.